JAMA Submission Process

This page is about workflow after you decide to submit.

Use it when you want to understand:

• what happens after upload
• how fast triage usually forms a view
• what the likely choke points are before and after peer review
• when JAMA is likely to redirect you toward a specialty title or JAMA Network Open

If you still need help deciding whether the package itself is ready, that belongs on the submission-guide page.

JAMA's instructions are unusually direct here. They state all submitted manuscripts are reviewed initially by one of the editors and evaluated on whether:

• the material is original and timely
• the writing is clear
• the study methods are appropriate
• the data are valid
• the conclusions are reasonable and supported by the data
• the information is important
• the topic has general interest to readers of this journal

That last line explains most fast rejections. JAMA is not only deciding whether the science is sound. It is deciding whether the paper deserves general-medicine attention.

The process goes much better when the manuscript already reads like a JAMA paper before the portal opens. That means:

• a broad clinical audience case is already visible
• the structured abstract and Key Points are doing real editorial work
• the paper is not relying on the journal name to create importance
• the data-sharing and reporting package already looks like something a statistical editor could trust

In other words, the process is smoother when the fit judgment was made honestly before upload.

JAMA has stricter initial submission requirements than any other top general medical journal. Expect to spend more time on formatting here than at The Lancet or NEJM.

Required for initial submission:

• manuscript formatted per JAMA style (AMA citation format, specific heading structure)
• structured abstract (350 words maximum, with Importance, Objective, Design/Setting/Participants, Interventions or Exposures, Main Outcomes and Measures, Results, and Conclusions and Relevance)
• cover letter
• all figures and tables (separate files)
• ICMJE conflict of interest forms for every author
• reporting checklist (CONSORT, STROBE, PRISMA, etc.) fully completed
• trial registration documentation (mandatory for interventional studies)
• data sharing statement
• statistical analysis plan (for trials)
• IRB or ethics documentation

Three things that make JAMA's requirements different:

1. The structured abstract and Key Points are part of the first screen. JAMA's abstract is tightly structured, and the instructions separately require Question, Findings, and Meaning Key Points in 75-100 words or less for research and review manuscripts. Filling those out properly takes judgment, not just reformatting.

2. AMA citation style from day one. Unlike journals that accept any citation format initially, JAMA expects AMA style from the first submission. If you're converting from Vancouver or another format, budget extra time.

3. The "Importance" section is unique to JAMA. The abstract opens with "Importance" rather than "Background." This isn't just a label change. It forces you to state why this question matters to general medicine before you describe what you did. Many authors treat it as a background paragraph and miss the point.

4. The Data Sharing Statement is part of the signal. JAMA expects front-end clarity about sharing, not a vague promise to sort it out after acceptance. A weak statement makes the paper look less operationally mature.

JAMA's editorial priorities differ from the other top generals in specific ways.

1. Methodological rigor is the entry ticket. JAMA's editors hold submissions to a high methodological standard and explicitly screen for appropriate methods, valid data, and conclusions supported by the data. An underpowered study, a post-hoc subgroup analysis presented as a primary finding, or a trial whose paper overclaims beyond the protocol starts from a weaker position immediately.

2. The question should matter to practicing physicians across specialties. Like NEJM, JAMA wants broad clinical relevance. But JAMA's interpretation of "broad" leans toward questions that affect primary care, prevention, screening, and health policy rather than toward specialized therapeutic interventions. A trial of a new cancer drug might fit better at NEJM. A trial of a screening strategy that primary care physicians would implement fits naturally at JAMA.

This is also why many solid papers are redirected rather than reviewed out. JAMA is not only asking "is this good?" It is asking "is this general medicine enough for the flagship?"

3. JAMA values evidence synthesis differently. JAMA publishes more systematic reviews and meta-analyses than NEJM or The Lancet. If your paper is a well-done systematic review on a clinically relevant question, JAMA is often the first choice. The Lancet and NEJM are harder targets for evidence synthesis alone.

4. Referral logic is part of the real process. The instructions explicitly let authors preselect referral to one of the JAMA Network specialty journals if the manuscript is not accepted by JAMA. That means an early no is often not a verdict on quality. It is a verdict on flagship fit versus specialty or network fit.

In our pre-submission review work with manuscripts targeting JAMA, three patterns generate the most consistent desk rejections. We see these across hundreds of clinical manuscripts we've reviewed through our JAMA submission readiness check, and they consistently predict the outcome before submission.

The specialty paper with a general-medicine cover letter. We find this pattern in roughly 40% of JAMA desk rejections we review. The paper is a well-designed cardiology trial, a solid oncology cohort study, or a rigorous nephrology analysis, but the clinical decision it informs is one that only specialists make. The cover letter claims "broad clinical relevance," but every result and every discussion point speaks to one specialty community. Editors routinely redirect these to JAMA Cardiology, JAMA Oncology, or JAMA Network Open. What actually happens at triage: the editor reads the Key Points and asks "would a family medicine physician change what they do tomorrow based on this?" If the answer is no, the paper is already heading to a Network title.

The "Importance" section that is actually a background paragraph. This sinks manuscripts that might otherwise survive the desk. JAMA's structured abstract requires "Importance" as the opening section, but we observe that roughly 50% of manuscripts we review open with "Previous studies have shown..." or "The role of X in Y remains poorly understood." That is background, not importance. The editor sees an author who doesn't understand what JAMA is asking for. In practice, the Importance section should answer one question: why should a general-medicine reader care about the answer to this study's question? Starting with what is unknown is different from starting with why the unknown matters to practicing clinicians.

The reporting checklist filled out as an afterthought. Per JAMA's author guidelines, completed reporting checklists (CONSORT, STROBE, PRISMA) are required at submission. We consistently find that manuscripts where CONSORT items are marked "N/A" without justification, where page numbers don't match the manuscript, or where the statistical analysis plan is vague trigger immediate editorial concern. JAMA's statistical editors actually read these checklists. In our experience, roughly 30% of papers we review have reporting checklist problems significant enough to trigger a desk reject or an immediate request for revision before review even begins.

The paper doesn't survive the methods-and-conclusions screen. JAMA's own criteria tell you what fails here: methods that don't match the claim, data that don't support the conclusion, or a paper whose writing isn't clear enough for general readers to trust quickly.

The reporting checklist is incomplete. JAMA editors actually read the CONSORT/STROBE/PRISMA checklist. A checklist where items are marked "N/A" without justification or where page numbers don't match the manuscript triggers immediate concern. Budget time to fill these checklists properly.

The paper is strong but too specialty-focused. A well-designed cardiology trial might be excellent science, but if the clinical decision it informs is one that only cardiologists make, JAMA's editors will redirect you to JAMA Cardiology. This isn't a quality judgment; it's a readership fit decision.

The "Importance" statement is actually a background paragraph. The most common abstract error at JAMA: starting the Importance section with "Previous studies have shown..." That's background, not importance. Start with why a physician reading this abstract should care about the answer.

The JAMA Network includes JAMA Internal Medicine, JAMA Cardiology, JAMA Oncology, JAMA Neurology, JAMA Surgery, JAMA Pediatrics, JAMA Network Open, JAMA Health Forum, and others. When papers are rejected from JAMA, authors can transfer to any JAMA Network journal with the reviews intact.

JAMA Network Open, in particular, is a common landing spot for papers that are methodologically solid but not quite broad enough for the flagship. That is the practical value of JAMA's referral logic: an early no may still leave you inside the network rather than forcing a full restart elsewhere.

That redirect logic is part of the real process, not an afterthought. Authors should read an early no from JAMA as a readership and flagship-threshold judgment first, not as proof that the science lacks value.

JAMA's published medians help, but authors still misread silence.

• very early quiet usually means internal triage and statistical screening against JAMA's explicit criteria for importance and general interest
• longer post-review quiet usually means synthesis across editor, reviewers, and possible redirect decisions
• a rapid no is often a readership-fit judgment, not proof the science is weak

The useful question is not just "how many days has it been?" It is "which part of JAMA's workflow is this manuscript plausibly in right now?"

If the manuscript is still in the earliest phase, the main question is usually fit plus reporting discipline. If it is already under review, the question has shifted toward methodologic confidence, statistical critique, and whether the findings justify flagship general-medicine attention after scrutiny.

How this page was created: this guide uses JAMA Instructions for Authors, JAMA journal information, ICMJE recommendations, JAMA Network transfer/referral materials, Clarivate JCR, and Manusights internal analysis of general-medicine submissions prepared for JAMA and adjacent JAMA Network titles. We did not test a private live JAMA Network portal session; portal and timing guidance is based on public JAMA materials and documented author experience.

In our analysis of JAMA-targeted submissions, the named failure pattern is a methodologically strong clinical paper that still does not make a general-medicine readership case in the abstract, Key Points, and cover letter. JAMA's public criteria include general interest to JAMA readers, so a paper can be high quality and still be redirected quickly.

What JAMA does well: fast front-door triage, explicit reporting requirements, strong statistical and editorial review, and a practical JAMA Network redirect path.

Where the process falls short for authors: initial formatting is demanding, reporting forms can delay evaluation, and a fast rejection can feel like a quality judgment when it is often a flagship-fit judgment.

Use this page when you are preparing the JAMA upload and interpreting the workflow. Use the JAMA journal profile when you are still deciding whether the flagship is the right target.

• JAMA Submission Guide
• Is JAMA a Good Journal?
• How to Avoid Desk Rejection at JAMA
• JAMA Impact Factor